Accumulation of major linezolid metabolites in patients with renal impairment

Ernane Souza, Ryan L. Crass, Jeremy Felton, Kengo Hanaya, Manjunath P. Pai

研究成果: Article

抜粋

In patients with renal impairment (n=22 of 39), the median serum concentrations of linezolid, PNU-142300, and PNU-142586 were 1.6-, 3.3-, 2.8-fold higher, respectively, than in patients without renal impairment. Metabolite concentrations in paired samples were poorly correlated with linezolid concentrations (r2 = 0.26 for PNU-142300 and 0.06 for PNU-142586). Linezolid and its metabolites share potential toxicophores that deserve characterization to mitigate higher myelosuppression risk in patients with renal impairment.

元の言語English
記事番号e00027-20
ジャーナルAntimicrobial Agents and Chemotherapy
64
発行部数5
DOI
出版物ステータスPublished - 2020 5 1

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

フィンガープリント Accumulation of major linezolid metabolites in patients with renal impairment' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用